). We report that cyclosporin A exacerbates disseminated leishmaniasis caused by L. donovani in C57BL/10 mice. Normal mice challenged with 5 x 106 amastigotes intravenously cleared the infection within several months by spontaneous acquisition of cell-mediated immunity. In contrast, cyclosporin A administered daily intraperitoneally at a dose of 1.25 mg per mouse prevented development of curative immunity and converted C57BL/10 (curing) mice to a noncuring phenotype. A rationale for the contrasting effects of cyclosporin A in the two murine models of leishmaniasis is provided.
Survival of the amastigote form of Leishmania species in the phagolysosomal compartment of tissue macrophages is a hallmark of these protozoan pathogens (8). Murine models of disseminated leishmaniasis have provided fundamental information regarding the acquisition of immunity against Leishmania major and L. donovani (2, 3, 6, 8, 10). There is a large body of evidence showing that protective immunity requires effective cell-mediated responses while antibody responses to the parasites play no positive role (8, 10) . A characteristic feature of disseminated leishmaniasis of humans and experimental animals is severe immune suppression involving cell-mediated responses. Although the mechanism of suppression is not fully understood, it is thought to be related to the appearance of suppressor T cells following amastigote parasitization of large numbers of tissue macrophages. The generation of suppressor T cells in experimental infections of mice can be blocked by cyclophosphamide (18) , sublethal irradiation (2, 13), or adult thymectomy (6). These immunomodulating measures have successfully converted noncuring strains of mice to a curing phenotype.
A much studied model of disseminated leishmaniasis utilizes L. major and BALB/c mice challenged subcutaneously. Cutaneous lesions in this strain of mice progressively enlarge until the infection eventually becomes systemic (6). With this experimental model, two groups of investigators independently reported that multiple injections of cyclosporin A (CyA) prevented progression of cutaneous lesions and fatal visceralization (1, 15). CyA, a fungal metabolite, is used extensively in human organ transplantation because of its potent immunosuppressive properties. Since CyA does not exert a direct toxic effect on amastigotes, Solbach et al. (15) of T lymphocytes and the release of interleukin-2, macrophage-activating factor, and gamma interferon (IFN--y) (4, 5, 14). Thus, CyA suppression is attendant with a reduced inflammatory response (1) and inhibition of macrophage accumulation at the site of infection. Solbach et al. (15) speculated that a paucity of macrophages in the skin lesions limited the severity of L. major infection in CyA-treated BALB/c mice. These mice, however, did not develop curative immunity since the inhibitory effects of CyA on macrophage-activating factor and IFN--y production prevented total elimination of L. major amastigotes within the residual macrophage population.
We considered it of interest to determine how CyA would modify the course of L. donovani infection in spontaneously curing C57BL/10 mice. Although this strain of mice is susceptible to L. donovani infection (Lshs), immunity and cure usually are achieved within several months (2, 12). Although both cutaneous (L. major) and disseminated (L. donovani) infections require effective cell-mediated responses for their resolution, it is now appreciated that, in susceptible murine hosts, the Lsh gene control of intrahepatic amastigote multiplication is operative only with L. donovani (3, 9). The course of L. donovani infection in CyA-treated C57BL/10 mice was followed so that the effects of the drug could be compared with the ameliorating effect of CyA on L. major infection in BALB/c mice (1, 15). Female C57BL/10 mice (Harlan, Indianapolis, Ind.) weighing 20 to 25 g were used throughout. L. donovani Sudan 1S amastigotes were obtained from spleens of infected hamsters as described previously (12) . One hundred mice were challenged intravenously with 5 x 106 amastigotes. CyA (Sandimmune, 50 mg/ml; Sandoz, East Hanover, N.J.) was diluted in phosphate-buffered saline. One 
